64 results
6-K/A
EX-99.2
QNTM
Quantum BioPharma Ltd
19 Aug 24
Condensed consolidated interim financial statements
5:18pm
loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations and arises principally from
6-K
EX-99.2
QNTM
Quantum BioPharma Ltd
14 Aug 24
Condensed consolidated interim financial statements
6:13am
loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations and arises principally from
6-K
EX-99.1
QNTM
Quantum BioPharma Ltd
8 Jul 24
Annual General and Special Meeting of the Shareholders to Be Held on Management Information Circular
5:16pm
or customer lists, business plans, computer software, company records and other proprietary information. The Code adopted by the Board provides for certain
6-K
EX-99.2
QNTM
Quantum BioPharma Ltd
15 May 24
Condensed consolidated interim financial statements
6:02am
payable and accrued liabilities.
FINANCIAL INSTRUMENTS AND OTHER INSTRUMENTS
Credit risk is the risk of financial loss to the Company if a customer
6-K
EX-10.1
3mkd44mjxo
20 Feb 24
FSD Pharma Announces US ATM Offering
6:01am
424B5
ucort3
16 Feb 24
Prospectus supplement for primary offering
6:36pm
F-3
hgf559j5sk
22 Dec 23
Shelf registration (foreign)
6:49pm
6-K
EX-99.2
0z9shxawdj
15 Nov 23
Condensed consolidated interim financial statements
12:00am
6-K
EX-99.1
5scdyk ct
25 Aug 23
FSD Pharma Signs Definitive Agreement to Launch UNBUZZD, a
4:18pm
6-K
EX-99.2
mivdk9cq 4oehobo0
20 Jul 23
Condensed consolidated interim financial statements
5:05pm
6-K
EX-99.1
pcv8ga4y
20 Jun 23
FSD Pharma Inc. 6-K
7:30am
6-K
EX-99.2
4gizpt8jp03scvnx6
12 May 23
Condensed consolidated interim financial statements
6:55pm
6-K
EX-99.2
mforvhvvtw00s9
14 Nov 22
Condensed consolidated interim financial statements
6:02am
6-K
EX-99.2
uyjf1nx
12 Aug 22
Condensed consolidated interim financial statements
4:58pm